Viewing stories from October, 2010

Quarterly Cashflow Report - September 2010

The cash balance at 30 September 2010 was $20.2m.  The Operating & Investing cash outflow of $2.4m for the quarter includes the set-up and upfront costs of the phase 2 bacterial vaginosis study for VivaGel® commenced in July.

Starpharma presents at ASX Small to Mid Caps conference, Hong Kong

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of 20 Australian companies, and one of only two Biotechs, selected to present at the third annual ASX Small to Mid Caps conference in Hong Kong. The ASX Hong Kong conference is part of a series of international investor events designed to showcase emerging Australian small and mid-cap listed companies to investors in Asia, Europe and the US.

Watch the presentation